6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB1) Receptor Inverse Agonists and Chemical Modifications for Peripheral Selectivity-Reference-Cited by-同舟云学术

6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB1) Receptor Inverse Agonists and Chemical Modifications for Peripheral Selectivity

Published:2018-10-19 Issue:22 Volume:61 Page:10276-10298
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Zhang Yue-Mei¹^ORCID,Greco Michael N.¹,Macielag Mark J.¹,Teleha Christopher A.¹,DesJarlais Renee L.¹,Tang Yuting¹,Ho George¹,Hou Cuifen¹,Chen Cailin¹,Zhao Shuyuan¹,Kauffman Jack¹,Camacho Raul¹,Qi Jenson¹,Murray William¹,Demarest Keith¹,Leonard James¹

Affiliation:

1. Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b01467

Reference51 articles.

1. The Highs and Lows of Cannabinoid Receptor Expression in Disease: Mechanisms and Their Therapeutic Implications

2. Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia

3. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study